Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Milvexian

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 68,504Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bayer Unveils Positive Phase III Anticoagulant Data
    Bayer Unveils Positive Phase III Anticoagulant Data

    23 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251123638167/en/Bayers-Asundexian-Met-Primary-Efficacy-and-Safety-Endpoints-in-Landmark-Phase-III-OCEANIC-STROKE-Study-in-Secondary-Stroke-Prevention

    BUSINESSWIRE
    23 Nov 2025
    Share Share
    Update On Phase 3 Librexia ACS Trial
    Update On Phase 3 Librexia ACS Trial

    15 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113242684/en/Update-on-Phase-3-Librexia-ACS-Trial

    BUSINESSWIRE
    15 Nov 2025
    Share Share
    Bristol Myers Squibb Presents Cardiovascular Portfolio Data
    Bristol Myers Squibb Presents Cardiovascular Portfolio Data

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103978786/en/Bristol-Myers-Squibb-Showcases-New-Long-Term-and-Real-World-Data-From-Cardiovascular-Portfolio-at-the-American-Heart-Association-Scientific-Sessions-2025

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program

    25 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230524005933/en

    BUSINESSWIRE
    25 May 2023
    Share Share
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications

    25 May 2023

    // PRESS RELEASE

    https://johnsonandjohnson.gcs-web.com/static-files/4120e707-3112-4f0b-a1d2-7015893e855c

    PRESS RELEASE
    25 May 2023
    Share Share
    BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian
    BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian

    03 Mar 2023

    // PRESS RELEASE

    https://news.bms.com/news/details/2023/The-Bristol-Myers-Squibb-Janssen-Collaboration-Launches-Pivotal-Phase-3-Librexia-Clinical-Trial-Program-Evaluating-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor/default.aspx

    PRESS RELEASE
    03 Mar 2023
    Share Share